EJS ACT-PD
@ejs-act-pd.bsky.social
The first MAMS trial looking for a neuroprotective treatment for Parkinson’s Disease will be launched in July 2025!
🌺 The EJS ACT-PD team at the #MovementDisorderCongress in Hawaii! 🌺
Members of the EJS ACT-PD team were delighted to attend the International Congress of Parkinson’s Disease and Movement Disorders in Honolulu this month.
#EJSACTPDTrial now launched to recruitment!
#MDSCongress #ParkinsonsResearch
Members of the EJS ACT-PD team were delighted to attend the International Congress of Parkinson’s Disease and Movement Disorders in Honolulu this month.
#EJSACTPDTrial now launched to recruitment!
#MDSCongress #ParkinsonsResearch
October 27, 2025 at 12:52 PM
🌺 The EJS ACT-PD team at the #MovementDisorderCongress in Hawaii! 🌺
Members of the EJS ACT-PD team were delighted to attend the International Congress of Parkinson’s Disease and Movement Disorders in Honolulu this month.
#EJSACTPDTrial now launched to recruitment!
#MDSCongress #ParkinsonsResearch
Members of the EJS ACT-PD team were delighted to attend the International Congress of Parkinson’s Disease and Movement Disorders in Honolulu this month.
#EJSACTPDTrial now launched to recruitment!
#MDSCongress #ParkinsonsResearch
🎉 That’s over 300 people already stepping forward to shape the future of Parkinson’s research. But we’re just getting started.
🔗 Simply scan the QR code or visit redcap.link/jpr1 to register!
#ParkinsonsDisease #ClinicalTrials #joinparkinsonsresearch #ParkinsonsCommunity
🔗 Simply scan the QR code or visit redcap.link/jpr1 to register!
#ParkinsonsDisease #ClinicalTrials #joinparkinsonsresearch #ParkinsonsCommunity
August 26, 2025 at 12:17 PM
🎉 That’s over 300 people already stepping forward to shape the future of Parkinson’s research. But we’re just getting started.
🔗 Simply scan the QR code or visit redcap.link/jpr1 to register!
#ParkinsonsDisease #ClinicalTrials #joinparkinsonsresearch #ParkinsonsCommunity
🔗 Simply scan the QR code or visit redcap.link/jpr1 to register!
#ParkinsonsDisease #ClinicalTrials #joinparkinsonsresearch #ParkinsonsCommunity
🧠 “The JPR registry will revolutionise how people like me find out about research.” – Phil, who has Parkinson’s & helped design JPR.
Help us connect more people to studies!
📰 Read more: tinyurl.com/JPRRegistry
🔗 Sign up: redcap.link/jpr1
📽️ Watch here: youtu.be/g900EDLZo5k
#ParkinsonsResearch
Help us connect more people to studies!
📰 Read more: tinyurl.com/JPRRegistry
🔗 Sign up: redcap.link/jpr1
📽️ Watch here: youtu.be/g900EDLZo5k
#ParkinsonsResearch
July 11, 2025 at 11:52 AM
🧠 “The JPR registry will revolutionise how people like me find out about research.” – Phil, who has Parkinson’s & helped design JPR.
Help us connect more people to studies!
📰 Read more: tinyurl.com/JPRRegistry
🔗 Sign up: redcap.link/jpr1
📽️ Watch here: youtu.be/g900EDLZo5k
#ParkinsonsResearch
Help us connect more people to studies!
📰 Read more: tinyurl.com/JPRRegistry
🔗 Sign up: redcap.link/jpr1
📽️ Watch here: youtu.be/g900EDLZo5k
#ParkinsonsResearch
Want to get involved in Parkinson’s Research? 🔊
We are excited to launch 'Join Parkinson’s Research' on Research+Me (JPR@Research+Me). Co-developed by Newcastle University and Research+Me in partnership with EJS ACT-PD.
Be first to hear when recruitment opens for the #EJS ACT-PD trial.
We are excited to launch 'Join Parkinson’s Research' on Research+Me (JPR@Research+Me). Co-developed by Newcastle University and Research+Me in partnership with EJS ACT-PD.
Be first to hear when recruitment opens for the #EJS ACT-PD trial.
May 7, 2025 at 3:35 PM
Want to get involved in Parkinson’s Research? 🔊
We are excited to launch 'Join Parkinson’s Research' on Research+Me (JPR@Research+Me). Co-developed by Newcastle University and Research+Me in partnership with EJS ACT-PD.
Be first to hear when recruitment opens for the #EJS ACT-PD trial.
We are excited to launch 'Join Parkinson’s Research' on Research+Me (JPR@Research+Me). Co-developed by Newcastle University and Research+Me in partnership with EJS ACT-PD.
Be first to hear when recruitment opens for the #EJS ACT-PD trial.